逆转西妥昔单抗耐药的药物及作用机制研究进展  

Research progress of drugs and mechanisms of action to reverse Cetuximab resistance

作　　者：孟瑾 张瑞 苏广珠 王潞 MENG Jin;ZHANG Rui;SU Guangzhu;WANG Lu(Department of Pharmacy,Shandong First Medical University,Jinan 250117,China;Department of Pharmacy,Jinan Mental Health Center,Jinan 250309,China;Department of Pharmacy,Central Hospital Affiliated to Shandong First Medical University,Jinan 250013,China)

机构地区：[1]山东第一医科大学药学院,山东济南250117 [2]济南市精神卫生中心药剂科,山东济南250309 [3]山东第一医科大学附属中心医院药学部,山东济南250013

出　　处：《药学研究》2025年第4期377-383,416,共8页Journal of Pharmaceutical Research

基　　金：山东省自然科学基金面上项目(No.ZR2023MH016);济南市临床医学科技发展计划项目(No.202134050);山东第一医科大学青年科学基金培育资助计划项目(No.202201-136)。

摘　　要：西妥昔单抗在临床上主要用于结直肠癌、胃癌等消化道肿瘤的治疗。然而,随着临床应用的不断深入,西妥昔单抗的耐药性问题日益凸显,极大限制了其广泛应用。即使西妥昔单抗对患者治疗有效,其缓解期最多持续12~18个月,之后几乎所有患者都会产生继发性耐药,导致治疗失败。因此,深入探讨西妥昔单抗的耐药机制并找到有效的逆转药物,对明确最佳的联合用药及靶向治疗模式、提高结直肠癌等肿瘤的治疗疗效具有重要意义。Cetuximab is mainly used in clinical practice for the treatment of gastrointestinal tumors such as colorectal cancer and gastric cancer.However,with the continuous deepening of clinical applications,the issue of resistance to Cetuximab has become increasingly prominent,greatly limiting its widespread use.Even if patients are effectively treated with Cetuximab,the remission period lasts up to 12~18 months,after which almost all patients develop secondary resistance,leading to treatment failure.Therefore,in-depth exploration of the resistance mechanism of Cetuximab and finding effective reversal drugs are of great significance for clarifying the optimal combination therapy and targeted treatment mode,and improving the therapeutic efficacy of tumors such as colorectal cancer.

关 键 词：西妥昔单抗 耐药 逆转耐药 药物作用 分子机制 

分 类 号：R979.1[医药卫生—药品]